INTRODUCTION
============

Dengue is an important arthropod-borne viral disease found worldwide. Dengue is caused by four serotypes of the genus *Flavivirus* (DENV-1, DENV-2, DENV-3, and DENV-4) and is transmitted via the bite of the *Aedes aegypti* mosquito, an urban vector that has adapted to human dwellings ([@b1-cln_68p1299]-[@b7-cln_68p1299]).

The worldwide incidence of dengue has increased over the past three decades. There are approximately 50 million symptomatic infections per year, and approximately two million cases require hospitalization, indicating that dengue is a serious global public health concern ([@b8-cln_68p1299]-[@b11-cln_68p1299]).

There is no vaccine or specific treatment for preventing the natural progression of the disease, and it is important that physicians have the appropriate tools to diagnose severe forms of dengue rapidly and accurately. This diagnosis requires a clinical classification system that provides simple and quick detection of patients who may develop more severe disease. It is especially important to detect plasma leakage, which is treated with intravenous rehydration, to reduce the mortality of dengue ([@b8-cln_68p1299],[@b10-cln_68p1299],[@b12-cln_68p1299]).

The 1997 World Health Organization (WHO) classification subdivides dengue into dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). The criteria for classifying a patient as having DHF are very rigid; the patient must exhibit four criteria: fever, hemorrhagic manifestations, thrombocytopenia, and evidence of third-space fluid loss (serous effusions, hemoconcentration, or hypoproteinemia) ([@b4-cln_68p1299],[@b6-cln_68p1299],[@b12-cln_68p1299]).

Several limitations to the practical applicability of these criteria have been noted, particularly in the evaluation of severe cases. Many patients who develop a severe clinical presentation do not meet the criteria for DHF and are ultimately classified as having dengue fever. In 2008, the WHO proposed a new classification system, based on a multicenter study in Asian and Latin American countries, that provided a list of clinical signs suggestive of a severe disease outcome (warning signs). This system classified dengue into dengue without warning signs (DWWS), dengue with warning signs (DWS), and severe dengue (SD) ([@b4-cln_68p1299],[@b6-cln_68p1299],[@b12-cln_68p1299],[@b13-cln_68p1299]).

The WHO dengue classification of 1997 aims to stratify dengue patients according to the pathophysiological level of disease progression, particularly with respect to the occurrence of plasma leakage. The WHO dengue classification of 2008 uses clinical signs and symptoms to stratify dengue patients according to disease severity ([@b4-cln_68p1299],[@b6-cln_68p1299],[@b12-cln_68p1299],[@b13-cln_68p1299]).

Based on this perspective, a cross-sectional survey was conducted to evaluate the ability of the two classification systems to detect severe cases of dengue based on the medical records of dengue patients who were admitted to the University Hospital of the Federal University of Grande Dourados during the dengue epidemic in the summers of 2009-2010. This study is the first in Brazil to evaluate the revised WHO classification criteria.

MATERIAL AND METHODS
====================

Data were collected through patient notification obtained from the National Notifiable Diseases Information System (SINAN) and the records of suspected cases of dengue at the University Hospital of the Federal University of Grande Dourados during September 2009 and April 2010 in Dourados, Mato Grosso do Sul. Indigenous patients and patients whose records could not be located were excluded. From the collected records, a survey of the following epidemiological data was conducted: gender, age, and city of residence. The clinical data obtained included reports of fever, headache, myalgia, arthralgia, retro-orbital pain, skin rash, vomiting, diarrhea, epistaxis, petechiae, gingival bleeding, metrorrhagia, hematuria, warning signs, abdominal pain, persistent vomiting, postural hypotension, hepatomegaly, gastrointestinal hemorrhaging, drowsiness/irritability, oliguria, hypothermia, respiratory distress, shock, hypotension, converging blood pressure, cold extremities, cyanosis, rapid and thready pulse, slow capillary refill, and serous effusions (pleural and peritoneal). The laboratory data included a complete blood count (hematocrit, hemoglobin, leukocyte count, and platelet count), liver enzymes (AST and ALT), and liver function tests (albumin, PT, and aPTT). The clinical outcomes included death, admission to the ICU, and the need for blood transfusions (packed red blood cells, plasma, and platelets). The clinical and laboratory data were collected within the first 24 hours of admission.

Dengue patients were classified retrospectively based on warning signs and disease severity. The warning signs were as follows: abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy/restlessness, liver enlargement greater than 2 cm, and an increase in the hematocrit concurrent with a rapid decrease in platelet count. The criteria used for SD were as follows: shock, fluid accumulation with respiratory distress, severe bleeding, AST or ALT greater than or equal to 1,000, impaired consciousness, and severe involvement of the heart and other organs.

These data were tabulated and analyzed to evaluate the primary variables associated with ICU admission and to compare the traditional and revised WHO clinical classifications regarding the development and clinical severity of disease. ICU admission was used as a proxy for disease severity.

The variables were entered into the database of the Epi-Data program, version 3.0, and analyzed using the SAS statistical software, version 9.1.

The distribution pattern of each variable was evaluated, and the statistical methods were selected based on the specific distribution pattern. The variables that exhibited an asymmetric distribution were evaluated using non-parametric tests, whereas those that exhibited a normal distribution were evaluated using parametric tests. Categorical or dichotomous data were analyzed using the chi-square test or Fisher\'s exact test when the number of subjects per cell was less than 5.

The study was approved by the committee for ethics in research of the Federal University of Grande Dourados under number 01304112.9.0000.5160.

RESULTS
=======

Between September 2009 and April 2010, 7,827 dengue cases were reported to the SINAN (3,913 cases per 100,000 inhabitants), and 495 (6.32%) patients were hospitalized. A total of 211 patients were admitted to the University Hospital of the Federal University of Grande Dourados. Twenty-four cases were excluded: 22 patient records could not be located, and 2 patients were indigenous people. The study included 187 patients from SINAN who were admitted to the University Hospital of the Federal University of Grande Dourados. Of these, 77 (41.4%) were male. The patients ranged in age from 1 to 90 years, with an average age of 37.1 years. The majority of patients (90.8%) lived in the city of Dourados ([Table 1](#t1-cln_68p1299){ref-type="table"}). During the epidemic, not all cases were confirmed; 160/187 (86%) patients underwent serological examination; 12% were negative, 57% were positive, and 31% were inconclusive for dengue.

The most common classical symptom of dengue was fever, which was present in 173 patients (98.3%), followed by myalgia (84.5%) and headache (78.1%). Warning signs were present in 108 patients (60.7%). Of these warning signs, the most frequent was abdominal pain, which was present in 92 patients (53.5%). Nineteen patients (11.4%) presented with signs of shock ([Table 1](#t1-cln_68p1299){ref-type="table"}).

Based on the traditional classification, the distribution of the patients in the study was 82.9% DF, 14.9% DHF, and 2.2% DSS. The revised classification placed DWWS at 24.3%, DWS at 59.1%, and SD at 15.6% ([Figure 1](#f1-cln_68p1299){ref-type="fig"}).

Of the 150 patients classified as having DF, 105 (70%) were reclassified as DWS or SD. None of the patients classified as DHF or DSS were reclassified as DWWS ([Table 2](#t2-cln_68p1299){ref-type="table"}). With the new classification, 96.2% of patients admitted to the ICU were classified as DWS/SD. By the traditional classification, 53.8% were classified as DHF/DSS (p = 0.4615) ([Table 3](#t3-cln_68p1299){ref-type="table"}). With the new classification, 71.8% of patients admitted to the ward were classified as DWS/SD, whereas by the traditional classification, 11.4% were classified as DHF/DSS (p = 0.0061) ([Table 4](#t4-cln_68p1299){ref-type="table"}). We found that the majority of the classical signs and symptoms were not associated with disease severity. Most of the warning signs were associated with an indication for ICU admission and were severe. The same results were observed for the variables associated with a specific outcome, such as death or the need for a blood transfusion ([Table 5](#t5-cln_68p1299){ref-type="table"}).

DISCUSSION
==========

This study was conducted during a major dengue epidemic in the state of Mato Grosso do Sul from September 2009 to October 2010. During the first 13 weeks of the epidemic in 2010, there were 59,199 reported cases of dengue statewide (13.2% of the cases reported nationally). Mato Grosso do Sul had the 4^th^ highest number of cases of any state in the country and the 2^nd^ highest incidence (2,507.8 cases per 100,000 inhabitants) ([@b14-cln_68p1299]).

The frequencies of the classical signs and symptoms, hemorrhagic manifestations, and warning signs of dengue fever observed in this study were similar to those of previously published studies ([@b15-cln_68p1299]-[@b17-cln_68p1299]). Laboratory data, such as platelet counts, were frequently recorded (73% of cases) and were consistent with the frequencies reported by Cortiñas et al. (70.5%), Barniol et al. (72%), and Mourão et al. (89.9%) ([@b6-cln_68p1299],[@b15-cln_68p1299],[@b16-cln_68p1299]).

Using the traditional 1997 WHO classification, the majority of patients were classified as having dengue fever (82.9%) ([@b18-cln_68p1299]). These data, although slightly higher, were similar in pattern to those reported by Mourão et al. (66.3%), Barniol et al. (67.1%), and Narvaez et al. (70.8%) ([@b4-cln_68p1299],[@b6-cln_68p1299],[@b16-cln_68p1299]). The use of the traditional classification system as a criterion for admission to the hospital was not useful. The majority of patients admitted to the hospital were classified as DF. Notably, 8.3% of the DF patients required ICU admission, indicating that the traditional classification was unable to identify the patients who developed more severe disease.

When the two classifications were compared, the majority of the DF patients (70%) were reclassified as DWS or SD. Similar data were reported in the studies by Barniol et al. (57.6%) and Narvaez et al. (93.4%) ([@b4-cln_68p1299],[@b6-cln_68p1299]). In the study by Narvaez et al., 6.6% of patients were reclassified as having dengue without warning signs ([@b6-cln_68p1299]).

The criteria for DHF were very rigid in the traditional 1997 WHO classifications. Patients could be classified as DHF if they presented with all of the following signs ([@b20-cln_68p1299]): fever for two to seven days, thrombocytopenia (≤100,000/mm^3^), hemorrhagic manifestations (positive tourniquet test, hemorrhagic skin, and mucosal bleeding), and plasma leakage due to increased capillary permeability (a 20% increase in hematocrit values over the baseline at admission, a 20% decrease in hematocrit values after the appropriate treatment, and the presence of pleural effusion, ascites, or hypoproteinemia).

The requirement of meeting all of the criteria caused difficulty in detecting severe cases. Several authors reported difficulties in determining the criteria and classifying patients as DHF ([@b4-cln_68p1299],[@b19-cln_68p1299]-[@b21-cln_68p1299]). In many situations, it is difficult to demonstrate hemoconcentration based on a 20% increase in hematocrit values; intravenous fluid replacement may alter hematocrit levels and hamper the use of this criterion. Many countries do not have a normal hematocrit value for their population, making it difficult to determine the 20% limit. Some researchers use hematocrit values to evaluate hemoconcentration during convalescence. This evaluation involves a retrospective diagnosis, which is not intended to predict the risk of developing severe disease ([@b6-cln_68p1299]).

Another limitation was the need to perform laboratory tests to diagnose DHF; these tests included hematocrit, platelet count, serum albumin, chest radiography, and abdominal ultrasound tests. The requirement for these tests could complicate the diagnosis in countries in which access to these tests is limited ([@b22-cln_68p1299]). These data demonstrate the low discriminatory power of the traditional classification in detecting severe cases of dengue. Previous studies have demonstrated that the level of detecting severe cases of dengue is 39% for the traditional classification and 92% for the revised classification ([@b6-cln_68p1299],[@b23-cln_68p1299]).

The increased discriminatory power of the revised classification can be explained by the requirement for a single criterion (warning sign) to classify a patient as being at risk of progressing to severe disease ([@b4-cln_68p1299]). The presence of shock, independent of thrombocytopenia or hemoconcentration, is sufficient to classify a patient as having SD ([@b4-cln_68p1299],[@b23-cln_68p1299]).

The classical signs and symptoms of dengue were not significantly correlated with the need for ICU admission. The majority of the warning signs that determine disease severity (with the exception of uncontrollable vomiting, hepatomegaly, and serous effusions) were strongly associated with ICU admission. These warning signs were significantly correlated with disease that resulted in death or the need for a blood transfusion.

By using the ICU as a proxy for the severity of illness, we demonstrated that the new classification is more sensitive (96.2%) than the traditional classification, but there is a significant loss of specificity (28.2%). Although patients admitted to the ICU have a higher frequency of warning signs, an indication for ICU admission should not be based on the presence of warning signs alone. Further studies with a larger sample size are necessary to assess the associated variables that could predict disease severity and ICU admission. Prospective studies involving outpatients should be performed to identify whether the new classification is important in indicating hospitalization in different settings.

This study has some limitations and potential confounding factors that are inherent in a retrospective design based on a secondary database. The results of this study are limited by the absence of important variables that may not be recorded in medical charts, including symptoms, physical exams, laboratory findings, and the use of intravenous rehydration. Another relevant limitation is using ICU admission as a proxy for disease severity. ICU admission may not represent all severe cases due to a lack of beds in an ICU. A less common limitation is that ICU admission could be related to the age or comorbidities of a patient.

We conclude that the revised WHO classification is more effective than the traditional classification for identifying severe cases of dengue. The revised classification exhibits greater practical applicability in developing countries such as Brazil because it is less dependent on complementary exams. The ability to appreciate and recognize the warning signs of the revised classification is essential for clinicians to identify patients at risk of developing severe disease and to determine an appropriate course of action on a per-case basis. Future research to evaluate the warning signs of patient outcomes and the cost-effectiveness of the new classification system is necessary to ascertain whether the new classification system requires further modification or whether elements of the two classification systems can be combined.

No potential conflict of interest was reported.
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###### 

The distribution of demographic, clinical, and laboratory data and the clinical outcomes of patients hospitalized with suspected dengue at the University Hospital of the Federal University of Grande Dourados from September 2009 to April 2010 (N = 187).

  Variable                                                   DF                       DHF and SSD             *p*-value
  ---------------------------------------------------------- ------------------------ ----------------------- -------------
  **Demographic data**                                                                                        
      Gender - Male, N (%)                                   63/150 (42.0%)           11/31 (35.5%)           0.5017
      Age, mean +/- SD                                       37.8 +/- 22.1            33.4 +/- 27.6           0.5124^a^
  **Clinical data**                                                                                           
      Fever, N (%)                                           140/142 (98.6%)          30/30 (100%)            0.5132
      Myalgia, N (%)                                         115/134 (85.8%)          19/24 (79.2%)           0.4029
      Headache, N (%)                                        96/122 (78.7%)           20/26 (76.9%)           0.8426
      Vomiting, N (%)                                        66/114 (57.9%)           19/25 (76.0%)           0.0926
      Arthralgia, N (%)                                      51/97 (52.16%)           6/19 (31.6%)            0.0941
      Skin rash, N (%)                                       44/92 (47.8%)            9/19 (47.4%)            0.9710
      Retro-orbital pain, N (%)                              42/95 (44.2%)            3/16 (18.8%)            0.0962^b^
      Diarrhea, N (%)                                        34/98 (34.7%)            11/24 (45.8%)           0.3107
  **Hemorrhagic signs**                                                                                       
      Petechiae, N (%)                                       63/124 (50.8%)           17/31 (54.8%)           0.6878
      Epistaxis, N (%)                                       21/116 (18.1%)           11/30 (36.7%)           0.0285
      Gingival bleeding, N (%)                               27/121 (22.3%)           6/29 (20.7%)            0.8496
      Metrorrhagia, N (%)                                    15/114 (13.2%)           3/29 (10.3%)            1.0000^b^
      Gastrointestinal hemorrhaging, N (%)                                                                    
      Hematuria, N (%)                                       7/113 (6.2%)             2/28 (7.1%)             1.0000^b^
  **Warning signs, N (%)**                                   **80**/**145 (55.2%)**   **28**/**31 (90.3%)**   **0.0003**
      Abdominal pain, N (%)                                  69/140 (49.3%)           23/30 (76.7%)           0.0063
      Serous effusions, N (%)                                14/136 (10.3%)           13/29 (44.8%)           \<0.0001
      Respiratory distress, N (%)                            11/131 (8.4%)            9/26 (34.6%)            0.0002
      Shock, N (%)                                           12/134 (9.0%)            7/31 (22.6%)            0.0322
      Hypotension, N (%)                                     11/129 (8.5%)            6/30 (20.0%)            0.0670
      Drowsiness/irritability, N (%)                         6/131 (4.6%)             10/30 (33.3%)           \<0.0001
      Postural hypotension, N (%)                            5/239 (3.9%)             4/36 (15.4%)            0.0438^b^
      Persistent vomiting, N (%)                             4/131 (3.1%)             3/29 (13.8%)            0.0366^b^
      Hepatomegaly, N (%)                                    5/132 (3.8%)             3/29 (10.3%)            0.1562^b^
      Hypothermia, N (%)                                     2/130 (1.5%)             4/30 (13.3%)            0.0954^b^
      Cyanosis, N (%)                                        2/127 (1.6%)             3/30 (10.0%)            0.0484^b^
      Oliguria, N (%)                                        2/130 (1.5%)             3/29 (10.3%)            0.0426^b^
      Rapid and thready pulse, N (%)                         2/127 (1.6%)             2/30 (6.7%)             0.1652^b^
      Cold extremities, N (%)                                1/127 (0.8%)             2/30 (6.7%)             0.0937^b^
      Slow capillary refill, N (%)                           1/127 (0.8%)             1/30 (3.3%)             0.3466^b^
      Converging blood pressure, N (%)                       0/127 (0%)               0/30                    
  **Laboratory data**                                                                                         
      Platelet count, mean +/- SD                            81,9 +/- 87,0            43,8 +/- 62,6           0.0219^a^
      Hematocrit, mean +/- SD                                37.9 +/- 5.0             39.1 +/- 6.7            0.2600^a^
      Hemoglobin, mean +/- SD                                12.4 +/- 2.0             12.8 +/- 2.8            0.6041^a^
      Leukocyte count, mean +/- SD                           2,1 +/- 1,7              2,3 +/- 1,5             0.6409^a^
      AST, mean +/- SD                                       99.1 +/- 63.9            1011.0 +/- 3226.7       0.0058^a^
      ALT, mean +/- SD                                       70.5 +/- 5.6             431.8 +/- 178.7         0.0002^a^
      Albumin, mean +/- SD                                   3.5 +/- 0.5              2.9 +/- 0.6             0.0010^a^
      TP, mean +/- SD                                        14.6 +/- 2.3             18.6 +/- 8.5            0.0026^a^
      aPTT, mean +/- SD                                      45.4 +/- 13.2            58.1 +/- 27.0           0.0254^a^
  **Clinical outcome**                                                                                        
      Death, N (%)                                           1/140 (0.7%)             2/28 (7.1%)             0.0724^b^
      ICU admission, N (%)                                   12/144 (8.3%)            14/31 (45.2%)           \<0.0001
      Length of hospitalization (days), mean +/- SD          3.5 +/- 3.5              8.8 +/- 10.2            \<0.0001^a^
      Length of hospitalization in ICU (days), mean +/- SD   5.5 +/- 9.3              10.2 +/- 12.4           0.3333^a^
      Blood transfusion, N (%)                               13/147 (8.8%)            11/29 (37.9%)           \<0.0001
      Packed red blood cells, N (%)                          5/147 (3.4%)             6/29 (20.7%)            0.0004
      Platelets, N (%)                                       8/147 (5.4%)             8/29 (27.6%)            0.0002
      Plasma, N (%)                                          3/147 (2.0%)             4/29 (13.8%)            0.0149^b^

N (number of patients), SD (standard deviation), AST (aspartate aminotransferase), ALT (alanine aminotransferase), PT (prothrombin time), aPTT (activated partial thromboplastin time), ICU (intensive care unit), ^a^ T-test, ^b^ Fisher Exact Test.

###### 

Correlations between the traditional and revised WHO classifications of patients with suspected dengue who were hospitalized at the University Hospital of the Federal University of Grande Dourados from September 2009 to April 2010.

          DWWS       DWS        SD         TOTAL   *p*-value
  ------- ---------- ---------- ---------- ------- -----------
  DF      45 (30%)   90 (60%)   15 (10%)   150     \<0.0001
  DHF     0 (0%)     17 (63%)   10 (37%)   27      
  DSS     0 (0%)     0 (0%)     4 (100%)   4       
  TOTAL   45         107        29         181     

DF (dengue fever), DHF (dengue hemorrhagic fever), DSS (dengue shock syndrome), DWWS (dengue without warning signs), DWS (dengue with warning signs), SD (severe dengue).

###### 

Correlations between the traditional and revised WHO classifications of patients with suspected dengue who were admitted to the Intensive Care Unit at the University Hospital of the Federal University of Grande Dourados from September 2009 to April 2010.

            DWWS       DWS/SD       TOTAL
  --------- ---------- ------------ -------------
  DF        1 (8.3%)   11 (91.7%)   12 (46.2%)
  DHF/DSS   0 (0%)     14 (100%)    14 (53.8%)
  TOTAL     1 (8.3%)   25 (96.2%)   26 (100.0%)

DF (dengue fever), DHF (dengue hemorrhagic fever), DSS (dengue shock syndrome), DWWS (dengue without warning signs), DWS (dengue with warning signs), SD (severe dengue).

###### 

Correlations between the traditional and revised WHO classifications of patients with suspected dengue who were admitted to the general ward at the University Hospital of the Federal University of Grande Dourados from September 2009 to April 2010.

            DWWS         DWS/SD        TOTAL
  --------- ------------ ------------- --------------
  DF        42 (31.8%)   90 (68.2%)    132 (88.6%)
  DHF/DSS   0 (0%)       17 (11.4%)    17 (11.4%)
  TOTAL     42 (28.2%)   107 (71.8%)   149 (100.0%)

DF (dengue fever), DHF (dengue hemorrhagic fever), DSS (dengue shock syndrome), DWWS (dengue without warning signs), DWS (dengue with warning signs), SD (severe dengue).

###### 

Clinical outcomes of patients with suspected dengue who were hospitalized at HU/UFGD from September 2009 to April 2010 based on demographic and clinical data compared with the need for ICU admission (N = 187).

  Variable                                             Patients admitted to the ICU   Patients not admitted to the ICU   *p*-value
  ---------------------------------------------------- ------------------------------ ---------------------------------- -------------
  **Demographics**                                                                                                       
      Gender - Male, N (%)                             12/27 (44.4%)                  92/104 (60.1%)                     0.1281
  **Clinical data**                                                                                                      
      Fever, N (%)                                     24/24 (100%)                   143/146 (97.9%)                    0.4786
      Headache, N (%)                                  14/19 (73.7%)                  99/127 (77.95%)                    0.6782
      Myalgia, N (%)                                   11/16 (68.7%)                  120/140 (85.7%)                    0.0797
      Arthralgia, N (%)                                3/10 (30.0%)                   52/104 (50.0%)                     0.3244^a^
      Retro-orbital pain, N (%)                        1/8 (11.1%)                    46/102 (45.1%)                     0.0760^a^
      Skin rash, N (%)                                 5/13 (38.5%)                   49/98 (49.0%)                      0.4756
      Vomiting, N (%)                                  15/18 (83.3%)                  66/118 (55.9%)                     0.0274
      Diarrhea, N (%)                                  8/17 (47.1%)                   36/103 (35.0%)                     0.3372
      Epistaxis, N (%)                                 4/21 (19.0%)                   15/122 (20.5%)                     0.8792
      Petechiae, N (%)                                 10/23 (43.5%)                  68/130 (52.3%)                     0.4349
      Gingival bleeding, N (%) (%)                     3/23 (13.0%)                   30/125 (24.0%)                     0.2907^a^
      Metrorrhagia, N (%)                              1/16 (5.9%)                    8/68 (11.8%)                       0.4687^a^
      Hematuria, N (%)                                 2/22 (9.1%)                    7/117 (6.0%)                       0.6339^a^
  **Warning Signs\*, N (%)**                           **24/26 (92.3%)**              **82/146 (56.1%)**                 **0.0005**
      Abdominal pain, N (%)                            17/23 (73.9%)                  74/143 (51.7%)                     0.0474
      Uncontrollable vomiting, N (%)                   2/19 (10.5%)                   5/137 (3.5%)                       0.2036^a^
      Postural hypotension, N (%)                      4/17 (23.5%)                   5/135 (3.7%)                       0.0097^a^
      Hepatomegaly, N (%)                              1/19 (5.3%)                    2/138 (4.4%)                       1.0000^a^
      Gastrointestinal hemorrhaging, N (%)             10/22 (45.5%)                  17/139 (12.2%)                     0.0001
      Drowsiness, N (%)                                8/21 (38.1%)                   8/137 (5.8%)                       \<0.0001
      Oliguria, N (%)                                  2/19 (10.5%)                   3/137 (2.2%)                       0.1126^a^
      Hypothermia, N (%)                               5/20 (25.0%)                   1/137 (0.7%)                       0.0021^a^
      Respiratory distress, N (%)                      8/18 (44.4%)                   12/136 (8.8%)                      \<0.0001
      Shock, N (%)                                     8/23 (34.8%)                   10/140 (7.1%)                      \<0.0001
      Hypotension, N (%)                               7/22 (31.8%)                   9/135 (6.7%)                       0.0003
      Converging blood pressure, N (%)                 0/21 (0%)                      0/134 (0%)                         
      Cold extremities, N (%)                          3/21 (14.3%)                   0/134 (0%)                         0.0022^a^
  Cyanosis, N (%)                                      3/21 (14.3%)                   2/134 (1.5%)                       0.0181^a^
      Rapid and thready pulse, N (%)                   4/21 (19.0%)                   0/134 (0%)                         \<0.0001^a^
      Slow capillary refill, N (%)                     2/21 (9.5%)                    00/134 (0%)                        0.0176^a^
      Serous effusion, N (%)                           13/20 (65.0%)                  19/47 (40.4%)                      0.0674
      Pleural effusion, N (%)                          7/16 (43.7%)                   7/32 (21.9%)                       0.1160
      Ascites, N (%)                                   8/18 (44.4%)                   15/32 (46.9%)                      0.8685
  **Clinical outcome**                                                                                                   
      Death, N (%)                                     3/22 (13.6%)                   0/148 (0%)                         0.0019^a^
      Blood transfusion, N (%)                         15/23 (65.2%)                  8/153 (5.23%)                      \<0.0001^a^
      Blood transfusion - packed erythrocytes, N (%)   9/23 (39.1%)                   2/153 (1.2%)                       \<0.0001^a^
      Blood transfusion - platelets, N (%)             10/23 (43.5%)                  6/153 (3.9%)                       \<0.0001
      Blood transfusion - plasma, N (%)                6/23 (26.1%)                   0/153 (0%)                         \<0.0001^a^

N (number of patients), ICU (intensive care unit), \* At least one warning sign, ^a^ Fisher Exact Test.
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